Cell Therapeutics Inc. (Nasdaq: CTIC)
Cell Therapeutics Inc. (CTIC) is a biopharmaceutical company engaged in the development and commercialization of oncology drug therapies for the treatment of cancer. Its portfolio of trial therapies include phase III candidate drug therapy Pixantrone, for the treatment of non-Hodgkin’s lymphoma; phase II drug Brostallicin, for the treatment of sarcoma; and OPAXIO for the treatment of non-small cell lung, ovarian, and other forms of cancer. The Company partnered with Novartis International Pharmaceuticals Ltd. and PG-TXL Company L.P. for various drug developments.
Popularity: 6% [?]
